Some experts believe this score should not be used as a single prognostic system in all histologic subgroups. Consider other prognostic systems.
Addition of selected points.
Facts & Figures
|% estimated cancer-specific survival rates|
|SSIGN Score||Year 1||Year 3||Year 5||Year 7||Year 10|
|0 - 2||99.7||98.7||97.3||96||93.6|
|3 - 4||98.1||93.4||89.8||84||77.9|
|5 - 6||92.9||83.8||74.1||65||57.3|
|7 - 9||76.5||46.9||38.6||29||25.9|
Original/Primary ReferenceFrank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumour stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395–400.
ValidationZigeuner R, Hutterer G, Chromecki T, Imamovic A, Kampel-Kettner K, Rehak P, Langner C, Pummer K. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010 Jan;57(1):102-9.
Other ReferencesLeibovich BC, Blute M, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663-1671Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012; 23(suppl 7):vii65–vii71.
About the Creator
Igor Frank, MD, is a professor of urology at the Mayo Clinic in Rochester, MN. Currently, he is the head of the Mayo Clinic bladder removal (cystectomy) registry. His research focuses mainly on treatment and prognosis of survival in bladder and prostate cancer, though he also researches continuity and quality of care for cancer patients.
To view Dr. Igor Frank's publications, visit PubMed